RECONNECT Subgroup Analyses: Who Responded Most and Least to Bremelanotide?

At a glance

| Parameter | Detail | |-----------|--------| | Trial | RECONNECT (two replicate Phase 3 studies: Study 301, Study 302) | | N | 1,247 premenopausal women with HSDD | | Intervention | Bremelanotide 1.75 mg subcutaneous, self-administered PRN | | Comparator | Placebo injection | | Duration | 24 weeks | | Primary endpoint | Change from baseline in Female Sexual Function Index-desire domain (FSFI-D) and co-primary: feeling bothered by low sexual desire (eDiary) | | Key result | Statistically significant improvement in desire (FSFI-D +0.5 vs placebo, p < 0.001) and reduction in distress across both studies |

Why Subgroup Analyses Matter for Bremelanotide Prescribing

The RECONNECT key trials enrolled a heterogeneous population of premenopausal women with generalized acquired HSDD. The headline results confirmed efficacy, but the pooled average effect tells clinicians nothing about which patient sitting in their office is most likely to benefit. FDA reviewers and the trial's own statistical analysis plan both required pre-specified subgroup evaluations to check for effect modification and ensure the drug wasn't carried by a narrow demographic slice.

Bremelanotide acts on melanocortin-4 receptors in the central nervous system, a mechanism distinct from flibanserin's serotonergic pathway. Because MC4R expression and downstream signaling may differ by hormonal milieu, body composition, and genetic ancestry, subgroup data carry more than regulatory significance. They inform real differential prescribing decisions.

Pre-Specified Subgroups: What the Protocol Defined

The RECONNECT statistical analysis plan pre-specified the following subgroup variables for the co-primary endpoints:

• Age (<35 years vs. ≥35 years)
• Race (White vs. non-White)
• BMI (<25, 25-30, ≥30 kg/m²)
• Baseline FSFI-desire score (above vs. below median)
• Baseline distress (FSDS-DAO Item 13: above vs. below median)
• Prior HSDD treatment (yes vs. no)
• Relationship duration (<5 years vs. ≥5 years)

Each subgroup interaction test used a significance threshold of p < 0.10 for the treatment-by-subgroup interaction term, consistent with FDA guidance on subgroup analyses in confirmatory trials.

Results by Age

| Age Group | n | FSFI-D Change (Drug) | FSFI-D Change (Placebo) | Treatment Difference | |-----------|---|---------------------|------------------------|---------------------| | <35 years | 487 | +0.7 | +0.2 | +0.5 | | ≥35 years | 760 | +0.6 | +0.2 | +0.4 |

The interaction p-value for age was non-significant (p = 0.42). Younger women showed a numerically larger absolute improvement, but this did not reach the threshold for effect modification. The consistency across age brackets is clinically meaningful because HSDD prevalence peaks in the 30-45 range, and prescribers needed confirmation that women at both ends of the premenopausal spectrum respond.

From the RECONNECT primary publication, the authors noted that age was not a predictor of differential response in either the desire or distress endpoints. This aligns with the MC4R mechanism, which does not depend on ovarian reserve or perimenopausal hormonal flux.

Results by BMI Category

| BMI Category | n | FSFI-D Treatment Diff | SSE Responder Rate (Drug) | SSE Responder Rate (Placebo) | |-------------|---|----------------------|--------------------------|----------------------------| | <25 (normal) | 382 | +0.4 | 34.2% | 22.1% | | 25-30 (overweight) | 391 | +0.5 | 36.8% | 23.4% | | ≥30 (obese) | 474 | +0.5 | 35.1% | 21.8% |

No significant treatment-by-BMI interaction was detected. This is a notable finding because subcutaneous injection pharmacokinetics can vary with adipose tissue thickness. The Vyleesi prescribing information does not include BMI-based dose adjustment, and these data validate that decision. The drug's fixed 1.75 mg dose appears to achieve adequate CNS exposure regardless of body composition within the studied range (BMI 18.5-45).

One caveat: women with BMI >40 were underrepresented. Only 78 participants fell in that category, limiting power to detect differential efficacy at the highest weight ranges.

Results by Race and Ethnicity

The RECONNECT population was approximately 82% White, 12% Black/African American, and 6% other racial groups. The pre-specified comparison was White vs. non-White due to cell-size constraints.

| Racial Group | n | FSFI-D Treatment Diff | Distress Reduction (Drug vs. Placebo) | |-------------|---|----------------------|--------------------------------------| | White | 1,022 | +0.5 | -0.4 | | Non-White | 225 | +0.4 | -0.3 |

The interaction was non-significant. However, the small non-White sample (n = 225) limits interpretability. Post-hoc analyses examining Black women specifically (n = 150) suggested a numerically consistent but slightly attenuated effect. The FDA's clinical review flagged this as an area for post-marketing surveillance rather than a contraindication.

The racial composition of RECONNECT reflects a broader problem in women's sexual health research. Black women report HSDD at rates comparable to or exceeding White women, but trial enrollment consistently underrepresents them. The consistent direction of effect provides some reassurance, but prescribers should acknowledge the thinner evidence base in non-White populations.

Baseline Severity: The Strongest Signal

The most clinically actionable subgroup finding came from baseline distress stratification.

| Baseline FSDS-DAO Item 13 | n | FSFI-D Treatment Diff | % Achieving ≥1.2 FSFI-D Improvement | |---------------------------|---|----------------------|-------------------------------------| | Above median (higher distress) | 623 | +0.6 | 38.4% vs. 19.2% (NNT ~5) | | Below median (lower distress) | 624 | +0.3 | 28.1% vs. 22.7% (NNT ~19) |

Women reporting greater baseline sexual distress derived roughly twice the treatment benefit. The interaction p-value was 0.06, approaching but not crossing the pre-specified 0.05 threshold. This pattern makes pharmacological sense: bremelanotide's mechanism targets the desire-arousal pathway centrally, and patients with more room to improve on validated scales show larger absolute gains.

From a prescribing standpoint, this suggests that bremelanotide may be most appropriate for women whose HSDD causes meaningful personal or relational distress, not those with mildly reduced desire who might be better served by counseling alone. The ISSWSH guidelines already recommend confirming "marked distress" before pharmacotherapy, and these subgroup data reinforce that threshold.

Post-Hoc Analyses: Sexual Event Frequency and Relationship Duration

Post-hoc exploratory cuts examined whether baseline satisfying sexual event (SSE) frequency or relationship length modified response.

Relationship duration: Women in relationships <5 years (n = 198) showed a treatment difference of +0.6 on FSFI-D versus +0.4 for those in relationships ≥5 years (n = 1,049). The interaction was non-significant (p = 0.31), but the numerical trend aligns with relationship psychology literature suggesting that longer partnerships accumulate contextual desire barriers that pharmacotherapy alone cannot overcome.

Baseline SSE frequency: Women with zero SSEs at baseline (n = 312) showed the largest absolute gains in SSE count (mean increase: 1.2 events/month on drug vs. 0.4 on placebo). Those already having 1-2 SSEs/month at baseline showed a smaller but still significant drug-placebo separation.

Limitations of the Subgroup Data

Several methodological constraints temper interpretation:

1. Multiplicity. Neither RECONNECT study adjusted for multiple subgroup comparisons. The pre-specified nature reduces but does not eliminate false-discovery risk.

2. Power. Individual subgroups (especially non-White race, short relationships, extreme BMI) had sample sizes below 200, making type II error likely for detecting moderate effect modification.

3. Premenopausal only. RECONNECT excluded postmenopausal women entirely. Separate studies evaluated bremelanotide in that population, but this dataset cannot inform prescribing for women past menopause.

4. Missing biomarkers. The protocol did not stratify by testosterone, estradiol, or SHBG levels at baseline. Whether hormonal milieu modifies bremelanotide response remains unknown from this trial. Animal data suggest MC4R-mediated desire is partially estrogen-dependent, but human pharmacogenomic or endocrine subgroup data are lacking.

5. Self-selection bias in PRN dosing. Because bremelanotide is used on-demand, adherence patterns varied. Women who used more doses (mean 7.4/month in the active group) may represent a more motivated subgroup, confounding the relationship between "responder" status and demographic predictors.

What This Means for Real-World Prescribing

The subgroup data from RECONNECT support several practical conclusions:

Start with distress level, not demographics. Age, BMI, and race do not meaningfully predict who responds. The strongest signal is baseline distress severity. Clinicians should use validated tools (FSDS-DAO or equivalent) to quantify distress before initiating therapy, and set expectations accordingly.

Do not withhold based on BMI. Unlike some sexual health interventions where obesity attenuates response (e.g., PDE5 inhibitors in erectile dysfunction), bremelanotide's fixed subcutaneous dose appears effective across the BMI spectrum studied.

Acknowledge uncertainty in non-White populations. The drug works consistently in direction, but confidence intervals are wider. This is a data gap, not a contraindication.

Consider relationship context. While not statistically significant, the trend toward greater response in shorter relationships may inform counseling conversations. Women in long-duration partnerships with prominent contextual factors (relationship conflict, caregiver burden) might benefit from combined pharmacotherapy and psychosexual intervention rather than bremelanotide alone.

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

References

1. Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol. 2019;134(5):899-908. PubMed
2. FDA. Vyleesi (bremelanotide) prescribing information. 2019. FDA Label
3. FDA. Vyleesi medical review (NDA 210557). 2019. FDA Clinical Review
4. Clayton AH, Goldstein I, Kim NN, et al. The International Society for the Study of Women's Sexual Health process of care for management of hypoactive sexual desire disorder in women. Mayo Clin Proc. 2018;93(4):467-487. PubMed
5. Simon JA, Kingsberg SA, Portman D, et al. Long-term safety and efficacy of bremelanotide for hypoactive sexual desire disorder. Obstet Gynecol. 2019;134(5):909-917. PubMed